Why is the DAPT Study important?
There is currently a lack of data within the international scientific community investigating the use of dual antiplatelet therapy for over one year following a drug-eluting stent placement. As a result, considerable uncertainty exists about whether the duration of dual antiplatelet therapy in patients receiving drug-eluting stents should be 12 months (as per the ACC/AHA guidelines) or longer in patients without contraindication. To provide data to answer this critical public health question, the U.S. FDA has asked the manufacturers of U.S. FDA-approved DES to conduct a postmarket study to investigate whether patients should continue dual antiplatelet therapy for more than one year following drug-eluting stent implantation.
